Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Pancreatic Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
25 drugs · 152 active trials
4 drugs · 116 active trials
8 drugs · 222 active trials
Outside the funnel: Phase not stated 1. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 15 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Oxaliplatin | Phase 3 | Phase 3 | 30 | 13 | 15 | 116 | 0 | — | — | 1998-04 |
| Leucovorin | Phase 3 | Phase 3 | 29 | 13 | 15 | 86 | 0 | — | — | 1995-08 |
| Cisplatin | Phase 3 | Phase 3 | 18 | 8 | 7 | 65 | 0 | — | — | 1997-05 |
| Chemotherapy | Phase 3 | Phase 3 | 12 | 6 | 4 | 24 | 0 | — | — | Apr 5, 2010 |
| Bevacizumab | Phase 3 | Phase 3 | 10 | 8 | 3 | 55 | 0 | — | — | 2002-02 |
| Cetuximab | Phase 3 | Phase 3 | 10 | 8 | 1 | 36 | 0 | — | — | 1999-10 |
| Docetaxel | Phase 3 | Phase 3 | 9 | 4 | 1 | 32 | 0 | — | — | 1999-07 |
| Tislelizumab | Phase 3 | Phase 3 | 8 | 3 | 1 | 13 | 0 | — | — | Jun 1, 2020 |
| Nimotuzumab | Phase 3 | Phase 3 | 6 | 2 | 3 | 11 | 0 | — | — | 2007-09 |
| Atezolizumab | Phase 3 | Phase 3 | 5 | 2 | 1 | 13 | 0 | — | — | 2016-11 |
| Panitumumab | Phase 3 | Phase 3 | 4 | 3 | 1 | 10 | 0 | — | — | 2000-04 |
| Camrelizumab | Phase 3 | Phase 3 | 3 | 1 | 1 | 7 | 0 | — | — | Aug 1, 2019 |
| FOLFOX Regimen | Phase 3 | Phase 3 | 2 | 2 | 2 | 11 | 0 | — | — | 2004-06 |
| Ruxolitinib | Phase 3 | Phase 3 | 2 | 0 | 2 | 9 | 0 | — | — | 2011-07 |
| Sunitinib | Phase 3 | Phase 3 | 1 | 0 | 1 | 7 | 0 | — | — | 2006-11 |
| Adjuvant Chemotherapy | Phase 3 | Phase 3 | 1 | 1 | 1 | 2 | 0 | — | — | Oct 13, 2016 |
| Setidegrasib | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Feb 17, 2026 |
| Thalidomide | Phase 3 | Phase 3 | 1 | 1 | 1 | 1 | 0 | — | — | Nov 1, 2023 |
| Ganitumab | Phase 3 | Phase 3 | 0 | 0 | 1 | 7 | 0 | — | — | 2007-06 |
| Mitomycin | Phase 3 | Phase 3 | 0 | 0 | 1 | 6 | 0 | — | — | 1997-09 |
| Celecoxib | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2003-03 |
| Sorafenib Tosylate | Phase 3 | Phase 3 | 0 | 0 | 1 | 5 | 0 | — | — | 2004-09 |
| Epirubicin | Phase 3 | Phase 3 | 0 | 0 | 1 | 4 | 0 | — | — | 2003-06 |
| Masitinib | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | Nov 25, 2008 |
| Pasireotide | Phase 3 | Phase 3 | 0 | 0 | 1 | 1 | 0 | — | — | 2009-10 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.